[ad_1]
Shanghai and Hongkong, December 16, 2021 /PRNewswire/ – Antengene Corporation Limited (“Antengene” SEHK: 6996.HK) is a leading innovative global biopharmaceutical company dedicated to the discovery, development and commercialization of first-class and/or first-class cancers and/or cancers drug. Other life-threatening diseases and XtalPi Inc is an artificial intelligence drug research and development company based on quantum physics. Its mission is to revolutionize drug discovery and development by improving speed, scale, novelty and success rate. Today, it announced a long-term R&D cooperation.
According to the terms of the agreement, XtalPi will utilize its integrated artificial intelligence (AI) research and development (R&D) platform, which consists of a proprietary cloud supercomputer-driven computer tool and its efficient wet laboratory to support Antengene’s drug discovery and development plan.
“This cooperation is in line with Antengene’s mission to provide first-class/first-class drugs for patients with cancer and other life-threatening diseases. We are very pleased to have the opportunity to accelerate the identification and selection of drug candidates through the cooperation with XtalPi for the synthesis and testing of silicon compounds. Pre-clinical evaluation. We believe that this technology will allow us to explore a broader chemical space, which is especially valuable for brand-new goals.” PhD. Jermaine, Founder and CEO of Antengene.
“This…
The full story can be found on Benzinga.com
[ad_2]
Source link
